Bastiaan Sallevelt

101 Evaluation of clarity of the STOPP/START criteria - SI Table SI1.4 Continued. STOPP Explanation Clarity rating n=77 C4 (no evidence of added benefit over clopidogrel monotherapy) . 83% C5 (no added benefit from aspirin). 83% C8 (no proven added benefit). 83% C9 (no proven added benefit). 83% D6 (risk of severe extra-pyramidal symptoms) 83% D13 (no evidence of efficacy) 83% E5 (risk of colchicine toxicity). 83% E6 (risk of lactic acidosis). 83% H9 (risk of relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture) 83% J3 (risk of suppressing hypoglycaemic symptoms). 83% L2 (risk of severe constipation). 83% B12 (risk of dangerous hyperkalaemia i.e. > 6.0 mmol/l – serum K should be monitored regularly, i.e. at least every 6 months). 92% C7 (clopidogrel and prasugrel have similar efficacy, stronger evidence and fewer side-effects).. 92% D3 (high risk of urinary retention). 92% D4 (risk of exacerbating or precipitating hyponatraemia). 92% D11 (risk of cardiac conduction failure, syncope and injury). 92% D12 since safer and more efficacious alternatives exist (phenothiazines are sedative, have significant anti-muscarinic toxicity in older people, with the exception of prochlorperazine for nausea/vomiting/ vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic in palliative care). 92% F1 (risk of exacerbating Parkinsonian symptoms). 92% J6 (risk of androgen toxicity; no proven benefit outside of hypogonadism indication). 92% D5 (no indication for longer treatment; risk of prolonged sedation, confusion, impaired balance, falls, road traffic accidents; all benzodiazepines should be withdrawn gradually if taken for > 2 weeks as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped abruptly). 100% F3 (risk of exacerbation of constipation). 100% 2